GW501516 (Cardarine) 20MG/ML
  • Load image into Gallery viewer, GW501516 CARDARINE PPAR AGONIST SARM
  • Load image into Gallery viewer, GW501516 (Cardarine) 20MG/ML

GW501516 (Cardarine) 20MG/ML

Regular price
Sale price
Regular price
Sold out
Unit price
Tax included. Shipping calculated at checkout.

Raider Crusader


CAS Number: 317318-70-0

Formula: C21H18F3NO3S2

Molar mass: 453.498 g/mol

Class: PPARδ receptor agonist

Application: Improvements to cholesterol balance, insulin sensitivity, endurance, speed, strength, fat burning.


Cardarine, or GW501516, is a PPAR (peroxisome proliferator-activated receptor) agonist that is often wrongly classified as a selective androgen receptor modulator (SARM). As a PPAR, it shares certain commonalities with SARMs but differs from them in a few important ways. Cardarine does not affect androgen receptors or alter testosterone levels.

Invented in the early 1990s, Cardarine is also known by a number of alternate names, including GW1516 and GSK-516. It is widely believed to provide a broad range of physical benefits, such as:

  • Burns fatty acids and promotes fat loss
  • Decreases LDL (“bad”) cholesterol
  • Increases HDL (“good”) cholesterol
  • Increases running endurance
  • Increases muscle mass and muscle fiber density
  • Reduces inflammation
  • Decreases the risk of atherosclerosis
  • Decreases insulin resistance
  • Reverses Type 2 diabetes
  • Increases cardiovascular health
  • Reduces exercise recovery times
  • Inhibits growth of cancer cells
  • Inhibits neurotoxicity

However, the benefits of GW501516/Cardarine have not been confirmed by the Food and Drug Administration (FDA) and the drug should be used for research purposes only.

Although there are no studies proving the beneficial effects of Cardarine in humans, a number of animal studies have been performed that point to the drug’s ability to enhance certain physiological processes.

  • One study on mice found that cardarine promotes fatty acid oxidation in skeletal muscles and alleviates metabolic syndrome. (T. Tanaka et al., Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome, Proc. Natl. Acad. Sci. U.S.A., vol. 100, no. 26, pp. 15924–15929, Dec. 2003.)1
  • Another study discovered that peroxisome proliferator-activated receptors can markedly increase running endurance in Kunming mice. (Chen, W. et al. A metabolomic study of the PPARd agonist GW501516 for enhancing running endurance in Kunming mice. Sci. Rep. 5, 09884; doi: 10.1038/srep09884 (2015).)
  • Yet another study on mice revealed that PPARs augment exercise endurance by preventing exhaustion of glucose (“hitting the wall”). (Fan W., Waizenegger W., Lin C.S., Sorrentino V., He M.-X., Wall C.E., Li H., Liddle C., Yu R.T., Atkins A.R., et al. PPARδ Promotes Running Endurance by Preserving Glucose. Cell Metab. 2017;25:1186–1193.e1184. doi: 10.1016/j.cmet.2017.04.006.)

Cited Research: Sports Technology Labs Research Blog


This preparation is for research purposes only and is not approved by the FDA for human use.